Provided by Tiger Trade Technology Pte. Ltd.

Merck

142.48
+0.54000.38%
Volume:3.73M
Turnover:532.84M
Market Cap:351.52B
PE:111.94
High:144.15
Open:142.00
Low:141.52
Close:141.94
52wk High:156.92
52wk Low:82.01
Shares:2.47B
Float Shares:2.47B
Volume Ratio:0.43
T/O Rate:0.15%
Dividend:3.32
Dividend Rate:2.33%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.38
PE(LYR):19.57

Loading ...

US Stocks on the MOVE-Halozyme, Moderna, Merck

Reuters
·
1 hour ago

Sector Update: Healthcare

MT Newswires Live
·
2 hours ago

Moderna, Merck Climb on Collaboration with Tempus

Reuters
·
3 hours ago

Merck's Keytruda is Dealt a Legal Setback. It's Good News for This Biotech Stock.

Dow Jones
·
3 hours ago

Halozyme Therapeutics Shares up 2% After Court Win Against Merck to Block Subcutaneous Keytruda in Select Markets

THOMSON REUTERS
·
Yesterday

Morgan Stanley Adjusts Price Target on Merck to $177 From $179

MT Newswires Live
·
Yesterday

Tempus AI announces multi-year collaboration with Moderna, Merck

TIPRANKS
·
Yesterday

Halozyme announces Dutch court of the Hague found Merck infringed patents

TIPRANKS
·
Yesterday

Tempus Expands Multi-Year Collaboration with Moderna, Merck on V940 Melanoma Vaccine Commercialization Support

Reuters
·
Yesterday

Halozyme Therapeutics - Iv Version of Keytruda Remains Available and not Covered by Halozyme's Patent or Court Injunction

THOMSON REUTERS
·
Yesterday

Halozyme Therapeutics - Court Rejects Merck's Arguments That Ep622 Patent is Invalid

THOMSON REUTERS
·
Yesterday

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda Sc in Multiple European Markets

THOMSON REUTERS
·
Yesterday

Halozyme Therapeutics - Court Orders Msd BV to Stop Keytruda Sc Manufacture and Sale in Eight European Countries

THOMSON REUTERS
·
Yesterday

Halozyme Therapeutics - Injunction Forbids Msd from Facilitating Infringement by Affiliates

THOMSON REUTERS
·
Yesterday

Tempus Announces Multi-Year Collaboration with Moderna and Merck

THOMSON REUTERS
·
Yesterday

Why Vaxcyte Chose A 1.5% Convertible

Macro World​
·
Yesterday

Will Drug Approvals Change Merck (MRK) Narrative

Simply Wall St.
·
Yesterday

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
Oct 06

Movement Alert|Merck Falls 3.13% in Regular Trading, Selling Pressure Prevails Despite Target Price Upgrades

Market Focus
·
Oct 05

Merck & Co Inc Stock (MRK) Moved Down by 3.04% on Oct 5: What Investors Need To Know

TradingKey
·
Oct 05